One Day After White House Signs $3.2 Billion Pfizer Deal, FDA Says Fall COVID Boosters Must Target Omicron Subvariants • Children's Health Defense

fda covid vaccine booster omicron variant

One Day After White House Signs $3.2 Billion Pfizer Deal, FDA Says Fall COVID Boosters Must Target Omicron Subvariants

The U.S. Food and Drug Administration said COVID-19 vaccine manufacturers will need to update fall boosters to target BA.4 and BA.5 Omicron subvariants, a day after the White House announced a $3.2 billion vaccine deal with Pfizer to include new boosters for subvariants.